No connection

Search Results

Regulation Score 55 Bearish

Eli Lilly CEO Opposes Codifying Trump-Era Drug Pricing Deals into Law

Apr 01, 2026 17:32 UTC
LLY, PFE, RXPh
Medium term

Eli Lilly's CEO Dave Ricks has publicly opposed the White House's attempt to turn the Trump administration's 'most favored nation' drug pricing agreements into law, warning of potential negative impacts on the pharmaceutical industry.

  • Eli Lilly opposes the White House's push to codify 'most favored nation' drug pricing into law.
  • Lilly and over a dozen drugmakers signed Trump-era pricing agreements in 2023.
  • The White House is now seeking to turn these agreements into federal legislation.
  • Lilly's CEO warns that the legislative process may alter the original intent of the agreements.
  • The company fears the policy could harm U.S. pharmaceutical innovation and research.
  • Lilly plans to use all available tools to oppose the legislation it deems harmful.

Eli Lilly's CEO Dave Ricks has voiced strong opposition to the White House's initiative to codify 'most favored nation' drug pricing agreements into federal law, as revealed in a recent interview with CNBC. The pharmaceutical giant, along with over a dozen other drugmakers, had previously signed deals with the Trump administration in 2023 to align U.S. prescription drug prices with those in other wealthy nations. These agreements were intended to address concerns about high U.S. drug costs and prevent legislative action on 'most favored nation' pricing. However, the White House has recently intensified efforts to push these terms into law, prompting Lilly's resistance. Ricks expressed skepticism about the legislative process, arguing that the final outcome may deviate from the original intent of the agreements. He emphasized concerns that the policy could undermine the U.S. pharmaceutical industry's ability to innovate and fund future drug development. While Ricks acknowledged that the Trump administration and congressional leaders are receptive to Lilly's stance, he indicated the company will actively oppose what it views as harmful legislation. The administration has not yet released a public draft of the proposed legislation but has encouraged pharmaceutical companies to support the effort. Lilly's position highlights the ongoing tension between cost-control measures and the sustainability of drug innovation in the U.S.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 75 Bullish

Eli Lilly's Obesity Drug Receives FDA Approval After Prolonged Review

Apr 01, 18:55

Score 35

Mamdani and City Council Clash Over $127 Billion New York Budget Plan

Apr 01, 17:20

Score 25

Options Bulls Eye Potential Upside in Major Pharma Stock

Apr 01, 17:05

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile